Pharma Journalist -

Aytu BioPharma, Inc. announced the signing of an exclusive agreement to commercialize EXXUA (gepirone) extended-release tablets ("EXXUA") in the United States. Gepirone is a new…
Read More...

Alnylam Pharmaceuticals, Inc. announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients…
Read More...

WuXi Biologics announced that it has kicked off construction of its new microbial manufacturing site for commercial production in the Wenjiang district of Chengdu, a renowned, vibrant…
Read More...

Cellectar Biosciences, Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, announced that the U.S. Food…
Read More...

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, announced it has secured…
Read More...

Camurus and Eli Lilly and Company have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, and…
Read More...

SpyGlass Pharma, a privately held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide…
Read More...

Roche announced that the European Commission (EC) has approved a label extension for Evrysdi (risdiplam) to include a new, room-temperature stable tablet for people living with spinal…
Read More...

Agenus Inc. announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd., including its subsidiaries/affiliates, hereafter referred to as “Zydus,” designed to…
Read More...

Bayer announced that the U.S. Food and Drug Administration (FDA) has approved its oral androgen receptor inhibitor, NUBEQA (darolutamide), for the treatment of adult patients with…
Read More...